When a Drug Launch Moves, the Business Changes Too
Roche's changing European plans raise questions about drug pricing, reimbursement and launch timing. Ron Lanton examines what these decisions mean for biotechnology companies and investors, following recent reporting by Maggie Fick in Endpoints News.
https://endpoints.news/roches-changing-plans-show-how-mfn-is-complicating-european-drug-launches/
COINS and Biotech: The Deal Structure May Matter More Than the License
Treasury’s proposed COINS rules may leave traditional pharma licensing outside core restrictions while creating new questions for equity, joint-venture and NewCo deals.
Could Switzerland Be Next? U.S. Drug Pricing Pressure Expands Beyond Germany
U.S. scrutiny of German drug pricing could extend to Switzerland and France. Ron Lanton examines how trade investigations, pharmaceutical pricing agreements, and tariffs may affect market access, launch decisions, and international commercialization.
How Europe May Respond to U.S. Drug Pricing Policies
U.S. drug pricing policy is raising concerns across Europe. Ron Lanton examines the European Parliament's response and what closer cooperation on pricing, reimbursement, and clinical assessments could mean for pharmaceutical companies.
PhRMA’s GLOBE Lawsuit: What the Case Could Mean for Medicare Drug Pricing
PhRMA’s GLOBE lawsuit challenges CMS authority to link Medicare Part B drug rebates to international prices. Here is what manufacturers and providers should watch.
Germany’s Drug-Pricing Investigation: When Trade Pressure Creates More Uncertainty
USTR’s Section 301 investigation into German drug pricing could affect reimbursement, launch timing and investment while placing further strain on U.S.–German trade relations.
AI + Healthcare, Part 3: AI’s Next Phase Is About Control, Not Speed
AI’s next phase will be defined not only by technical speed, but by governance, data protection, accountability and measurable value.